IDT has expanded its Coralville manufacturing footprint—boosting synthesis capacity to meet the rapidly growing demand for MRD assessment and NGS-based oncology research workflows. Read more: https://ow.ly/WYoW50YMFyM

#MRD #NGS #Oncology #ManufacturingExcellence #GenomicsInnovation

Thanks to our new Ansa partnership, we cover every dimension of DNA complexity—from fast fragments to 50 kb sequence-perfect constructs. Expect fast turnaround, best-in-class synthesis, and sequence-perfect DNA, so your boldest ideas don’t have to wait. Start here: idtb.io/07t7jr

Discover our xGen™ and Archer™ NGS portfolios at #AACR26!
Meet IDT’s trusted experts at Danaher’s booth #4217 and learn why leading oncology researchers trust our NGS solutions for their work in MRD, MCED, heme, and beyond. Learn more here: https://ow.ly/P0qe50YCqiU

#AACR2026 #NGS

As #CRISPR programs move closer to the clinic, confidence in gene editing safety becomes just as critical as editing efficiency. Our CRISPR Off-target Analysis Services are designed to help you identify and prioritize off-target edits early—so you can advance with clarity: https://idtb.io/cgov2wdq

Attending AACR? IDT Scientist David Knupp will present his poster on how our improved Archer™ VARIANTPlex™ workflow reduces assay time and enhances sensitivity. Come curious! Details below.

Learn more here: https://ow.ly/YVmM50YCqcu

#AACR2026 #NGS #nextgenerationsequencing

Want to achieve scalable, high-fidelity gene editing workflows that can efficiently transition from discovery to clinical evaluation? Join IDT and Aldevron for our free webinar that breaks down a translational, regulatory-aligned framework for non viral #CRISPRgeneediting: https://ow.ly/HpjA50YH7ky

We’re proud to collaborate on a new Danaher Beacon that aims to improve the reliability and scalability of cell and gene therapy workflows. Together with SR‑TIGET, this approach plans to accelerate the path from genome editing research to real‑world impact. Read more: https://okt.to/aUoL2e

Counting down the days until #AACR26! 🙌 IDT’s trusted experts are excited to meet you at Danaher booth #4217 to discover how our quality #NGSsolutions power over 80% of the #MRD market. Learn more: https://ow.ly/f6AT50YCq2f

#AACR2026 #NGS #nextgenerationsequencing

Attention CRISPR Medicine Conference attendees: Catch us on the main stage! Ashley Jacobi will be speaking about how our custom guide RNAs and CRISPR off-target solutions can support you from early research to therapeutic development. Show details: https://event.fourwaves.com/crisprmed26/pages

Boost your edits and fast-track your breakthrough. 🚀
Learn how our Alt-R™ HDR Enhancer Protein improves CRISPR knock-in efficiency by promoting HDR pathway precision—seamlessly integrated into workflows.

Full video here: https://idtb.io/8w38y8
Discover what’s possible here: https://idtb.io/fov3yc

This year's symposium is sponsored by @10xgenomics.bsky.social @idtdna.bsky.social

If you're here with us at #OxSymp26 today, make sure to visit their stalls during the breaks!

We’re heading to Copenhagen for CRISPR Medicine Conference! Come visit our experts at booth #B1 to discover how our high-quality reagents, design tools, and end-to-end CRISPR workflow solutions have the power to accelerate research and therapeutic progress: https://event.fourwaves.com/crisprmed26

Great to welcome representatives from @idtdna.bsky.social to Macquarie University last week for a tour of our Centre and Australian Genome Foundry. We discussed a variety of ways to engage with synthetic biology at Macquarie. Looking forward to future collaboration. 🤝

ICYMI: We’ve entered the #IVD market! IDT’s latest innovations—Archer FUSIONPlex™-HT Dx and VARIANTPlex™-HT Dx—will equip molecular pathologists with compliant in vitro diagnostics, without comprising innovation. Read more: https://idtb.io/4sup2b

#invitrodiagnostics #NGS #molecularpathology

Too complex? Too long? Not a prob. We cover every dimension of DNA complexity—from fast fragments to 50 kb sequence-perfect constructs in partnership with Ansa. Expect fast turnaround, dependable delivery, and sequence-perfect DNA, so your boldest ideas don’t have to wait: idtb.io/07t7jr

From sample to sequencer: IDT’s driving force behind the MRD revolution In the world of precision oncology research, minimal residual disease (MRD) has become one of the most promising areas of advancement and innovation. The ability to identify trace amounts of cancer re...

IDT has been a driving force in the #MRDresearch market since the earliest days of the field. From sample to sequencer, our end to end capabilities and expertise continue to enable innovation and help shape the future #MRD landscape. Read more from Ajay Gannerkote: www.linkedin.com/pulse/from-s...

We are extremely proud to announce our entry into the NGS in vitro diagnostics (IVD) market. Introducing Archer FUSIONPlex™-HT Dx and VARIANTPlex™-HT Dx. These solutions will equip molecular pathologists with compliant in vitro diagnostics, without comprising innovation: https://idtb.io/z38bju

Tune in to The Beat featuring IDT President, Ajay Gannerkote. Understand how precision oncology is leading the way for cancer care, how breakthroughs in #MRDassessment and #MCED are transforming cancer, and how our #NGSsolutions are powering the research behind this progress: https://bit.ly/44yJYV1

We're honored to be a part of the work that earned Danaher the 2026 ASGCT Catalyst Award—recognizing the cross-company collaboration behind the pioneering personalized #geneediting therapy developed for Baby KJ: https://ow.ly/huKr50Ysmmw

Move beyond limitations! When complexity stops others, we keep going. We’ve partnered with @ansabio.bsky.social to provide you with long, complex clonal DNA up to 50 kb. Expect fast turnaround, dependable delivery, and sequence-perfect DNA, so your boldest ideas don’t have to wait: idtb.io/07t7jr

"We can never do enough early collaboration.” 🤝
At #PMWC26, IDT President Ajay Gannerkote shared that early partnership is essential to accelerating innovations in #MRD. The panel explored how breakthroughs in cfDNA and cfRNA profiling are reshaping MRD, and transforming the future of oncology.

We’ve made it to #PMWC26! Attendees—remember to:

👉Stop by booth #B722 to speak with IDT experts about how we’re powering over 80% of the MRD research market.
👉Attend IDT President Ajay Gannerkote’s panel on advancing MRD detection through cfDNA and cfRNA profiling (today, March 4, 11:00 a.m.).

🗣"IDT is investing boldly in the next era of next generation sequencing." ✨
Last week, IDT President Ajay Gannerkote delivered a bronze sponsor talk at #AGBTgm titled "Accelerating enhanced genomic solutions", discussing strategies and real-world insights designed to accelerate discovery.

Just before #RareDiseaseDay, we’re reminded that although rare conditions affect smaller populations, together they represent a large unmet need in global health. Demaris Mills shares how tailored #geneediting therapies could transform care for those affected: www.forbes.com/councils/for...

Ajay Gannerkote will be speaking about advancing #MRD detection through cfDNA and cfRNA profiling at #PMWC26!

Join Ajay’s panel to explore how cfDNA and cfRNA profiling are helping to advance MRD detection and reshape the future of cancer care.

Learn more: pmwcintl.com/session/mar-...

#AGBTgm is here! Catch Nika Grillmeyer and Konstantin Fiedler as they share their day-one excitement, highlight IDT’s newest innovations, and talk about what they’re looking forward to this week. Visit the Nassau Suite to learn how our NGS portfolio is powering discoveries in cancer research.

#AGBT ATTENDEES! 🥼
Need reasons to stop by Nicholas Downey's and Katelyn Larkin’s poster presentations? We’ve got you covered. Come learn about IDT's new innovations in practice from 1:30-3:30 today, February 24. Look out for posters #419 and #441! #AGBTgm #AGBT26

We've made it to Orlando for #AGBT26! 🤩
We're in the Nassau Suite ready to chat about how our NGS portfolio is powering discoveries across the #cancerresearch continuum with unmatched customization, streamline workflows, and innovations that scale complex applications with confidence. Come say hi! 👋

We are excited to attend the Precision Medicine World Conference (#PMWC26) this year! Join us at booth #B722 to explore how IDT supports over 80% of the #MRDresearch market with high quality manufacturing, advanced technologies, and trusted partnerships.

Learn more: pmwcintl.com

We’re excited to unveil IDT’s latest #NGS innovation roadmap—purpose-built to accelerate cancer breakthroughs and empower researchers working at the forefront of precision #oncologyresearch. 👏

Read more here: idtb.io/pa7j4h

#cancerresearch #precisiononcology #precisionhealth